공시 • Oct 15
Absci Announces Accelerated Initiation of Phase 1/2a Trial
Absci announced the company will host a virtual seminar on December 11, 2025 at 10:00am ET focused on the company's ABS-201 (anti-PRLR) program for androgenetic alopecia. Additionally, Absci now expects to initiate the Phase 1/2a trial for this program in early December, ahead of prior guidance for early 2026, with an interim efficacy readout anticipated in the second half of 2026. The seminar to be hosted on December 11 will feature leading KOLs in the dermatology and hair loss fields, and highlight the clinical trial path, differentiated profile, and market potential of the ABS-201 program. KOLs presenting at this event include: Dr. David J. Goldberg, MD, JD, Clinical Professor of Dermatology at the Icahn School of Medicine at Mountinai. Mike Jafar, Medical Aesthetics Executive. Dr. Ralf Paus, M.D., D.Sc., F.R.S.B., Research Professor of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine. Dr. Anthony Rossi, MD, Attending Dermatologist, Memorial Sloan Kettering Cancer Center; Professor of Dermatology, Weill Cornell Medical College; Dr. Rodney Sinclair, MBBS, MD, FACD, Professor of Dermatology at The University of Melbourne and Director of Sinclair Dermatology. The webinar will begin at 10:00 a.m. Eastern Time and feature presentations on the latest developments and status of the ABS-201 program, followed by an interactive Q&A session. About ABS-201 and Androgenetic Alopecia: Androgenetic alopecia, commonly known as male-pattern or female-pattern hair loss, affects approximately 80 million Americans alone. The condition causes crown balding and receding hairlines in men, and progressive hair thin in women. Currently, the only FDA-approved treatments - minoxidil and finasteride - show limited efficacy and notable side effects, leaving patients with limited therapeutic options. ABS-201 represents a novel therapeutic approach targeting prolactin receptors to stimulate hair follicle regeneration and promote durable hair regrowth as demonstrated in vivo studies. In preclinical studies, the antibody demonstrated statistically significant superior hair regrowth compared to minoxidil in preclinical mouse models. Phase 1/2a clinical trials are planned to begin in December 2025, with initial proof-of-concept data expected in the second half of 20 26. About Absci: Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Integrated Drug Creation™? platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci's approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines data and strengthens models, facilitating rapid innovation and enhancing the precision of therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) Absci's preclinical studies, clinical trials, as well as partnered and internally developed programs, including, without limitation, manufacturing capabilities, status of such studies and trials and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described oral presentation, as well as the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials; (iii) Absci's strategy, goals, anticipated financial performance and the deficiency of the Company's strategy, goals, anticipated Financial performance and the deficiency of the company's financial performance of the Company's financial performance and the financial performance and financial performance and the financial performance.